Werkgroep Cardiologische centra Nederland

Dal-OUTCOMES (Completed)

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients.
Medicine
cetp-remmer
Population
ASCVD
Phase
III
Starting year
2008
More information
ClinicalTrials.gov

Director of Study

dr. A.H. Liem (Cardioloog)
Rotterdam, Franciscus Gasthuis

Dal-OUTCOMES: News